"The company reports that the doses of the vaccine administered to
healthy volunteers in the phase I clinical trial, which began on July
15, 2020, has been well tolerated," Cadila Healthcare, the listed
entity of the group, said in a regulatory filing. Zydus Cadila
Chairman Pankaj R Patel said the phase I dosing to establish the
safety of ZyCoV-D is an important milestone.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-to-commence-phase-ii-clinical-trials-of-covid-19-vaccine-zycov-d-from-aug-6/articleshow/77366409.cms
No comments:
Post a Comment